CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Cytek Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$5.25+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $679.67M
- P/E (TTM)
- –
- Dividend yield
- –
Cytek Biosciences statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Laboratory Analytical Instruments companies for comparison
Valuation
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Market Cap | $682.41M | $230.55M |
| Enterprise Value | $608.57M | $202.97M |
| PS Ratio | 3.30 | 3.11 |
| PB Ratio | 2.12 | 3.14 |
| P/TBV Ratio | 2.35 | 4.57 |
Enterprise value
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| EV / Sales | 2.94 | 2.92 |
Income (trailing twelve months)
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Revenue | $206.71M | $102.39M |
| Gross Profit | $110.03M | $60.36M |
| Operating Income | -$44.65M | -$4.31M |
| EBITDA | -$36.96M | -$1.98M |
| EPS (Diluted) | -$0.62 | -$0.07 |
Margins
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Gross Margin | 53.2% | 55.1% |
| Operating Margin | -21.6% | -6.04% |
| EBITDA Margin | -17.9% | -2.67% |
| FCF Margin | -5.84% | -0.30% |
Returns
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Return on Invested Capital (ROIC) | -12.8% | -4.11% |
| Return on Capital Employed (ROCE) | -12.3% | -9.07% |
Growth
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 5.44% | 8.85% |
| FCF Growth (YoY) | -211.1% | 10.6% |
| Revenue Growth (3Y CAGR) | 7.10% | 7.08% |
| Revenue Growth (5Y CAGR) | 209.5% | 11.8% |
Balance sheet
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $73.85M | $37.33M |
| Net Cash (Debt) | $73.85M | $3.92M |
| Net Cash Per Share | $0.57 | $0.28 |
| Equity (Book Value) | $321.95M | $57.36M |
| Book Value Per Share | $2.48 | $2.81 |
| Tangible Book Value | $290.40M | $10.71M |
| Working Capital | $293.60M | $54.64M |
Financial position
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Current Ratio | 4.48 | 2.50 |
| Quick Ratio | 1.46 | 1.54 |
| Interest Coverage | -143.11 | -1.81 |
Cash flow (trailing twelve months)
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Operating Cash Flow | -$6.04M | -$653.46K |
| Capital Expenditures | -$6.04M | -$3.69M |
| Free Cash Flow | -$12.08M | -$835.02K |
| FCF Per Share | -$0.09 | -$0.02 |
Efficiency
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Asset Turnover | 0.44 | 0.59 |
| Inventory Turnover | 1.90 | 2.21 |
| Revenue Per Employee | $294.46K | $322.57K |
| Employee Count | 702 | 185 |
Dividends and yields
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| FCF Yield | -1.77% | -0.56% |
| Buyback Yield | -0.01% | 0.78% |
| Shareholder Yield | -0.01% | 0.80% |
Shares
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Shares Outstanding | 129,983,000 | 44,856,700 |
| Shares Change (YoY) | -0.63% | 3.35% |
| Shares Change (QoQ) | 0.65% | 0.27% |
| Float | 116,245,000 | 37,097,900 |
| Shares Held by Insiders | 10.6% | 10.6% |
| Shares Held by Institutions | 62.7% | 63.5% |
Taxes
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Income Tax | $39.76M | $1.52M |
Scores
| Measure | Cytek Biosciences | Industry median |
|---|---|---|
| Altman Z-Score | 3.78 | 1.95 |
| Piotroski F-Score | 3 | 5 |
| Beneish M-Score | -3.29 | -2.64 |
Calculated by StockData from Cytek Biosciences's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.